3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Targeted therapies in multiple myeloma.

      Targeted Oncology

      Antibodies, Monoclonal, immunology, therapeutic use, Antineoplastic Agents, Cell Proliferation, drug effects, Cell Survival, Clinical Trials as Topic, Drug Design, Enzyme Inhibitors, pharmacology, Humans, Insulin-Like Growth Factor I, antagonists & inhibitors, Interleukin-6, Multiple Myeloma, drug therapy, metabolism, pathology, NF-kappa B, Signal Transduction, Vascular Endothelial Growth Factor A, Animals

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Increasing knowledge of the biology of multiple myeloma led the way for the development of novel drugs that have changed the management of the disease. New treatments target not only to the malignant plasma cell but also target the interactions of myeloma cells with their microenvironment. Several preclinical studies have identified potential targets and drugs are developed that act on pathways crucial for myeloma cell survival, proliferation, migration and drug resistance. The identification of active agents in the laboratory is followed by rationally designed clinical studies that validate these drugs, either as single agents or in combinations with other active drugs. These novel agents may be either small molecules or monoclonal antibodies targeting receptors, kinase activity of receptors or key molecules within critical pathways, intracellular maintenance mechanisms and immune modulation.

          Related collections

          Author and article information

          Journal
          19343299
          10.1007/s11523-008-0102-9

          Comments

          Comment on this article